Laila Gharzai MD LLM

Pre-COVID world traveler, wannabe foodie, and cancer zapper @NorthwesternMed Radiation Oncology #radonc #hncsm #lcsm

[Lurie Cancer Center @LurieCancer]

On Saturday, May 30, Laila Gharzai, MD, LLM, (@LGharzai) and Devalingam Mahalingam, MD, PhD, (@DevaMahalingam) showcased their research during the Poster Session.

Session Chair Priya U. Kumthekar, MD discussed #CentralNervousSystemTumor in her Oral Abstract Session. @ASCO

[Laila Gharzai MD LLM @LGharzai]

@NicholasZaorsky @UHhospitals @RadOncUH @CWRUSOM Wishing you the best Nick—I’m sure you’ll continue to be successful.

[Kamran Mahmood @kmahmood1970]

Great session at CHEST 2025 to discuss changes and implementation challenges of TNM-9 Staging of Lung Cancer. @accpchest @AAB_IP @wabipconnect @DukePulmFellows @DukeSurgery @DukeCancer @DukeCancerNTWK @DukePACC

[Fumiko Ladd Chino, MD, FASCO @fumikochino]

Dr @LGharzai on medical debt in pts receiving #radiation. #ASTRO25

Most had OOP expenses (61.1%, n=8701), mean $825.80 (SD 2114.5), median $25 (IQR 0-685.90).

Few had bad debt (2.7%, n=397), with a mean of $1109.90 outstanding (SD 4215.5) after a mean of 9.3 mo (SD 3.9).

[Public Health & Medicine (IPHAM) @NorthwesternU @nu_ipham]

Throat cancer survivor Paula Ruska and her doctor, @LGharzai , mark National #cancersurvivormonth by sharing their experience and discussing the need for continued care after treatment.

https://t.co/5ap8ywlX0Q

[Radiology Business @RadiologyBiz]

Unmet needs such as transport and finances forcing cancer patients to miss imaging appointments. @UCIMedSchool @RadiologyACR @JACRJournal @LGharzai https://t.co/yq641d3MKK

[Laila Gharzai MD LLM @LGharzai]

Our team demonstrates the first ever validation of COST Item 12 as a single item screening measure for financial toxicity—can be used as a brief, single item screener with excellent sensitivity for detecting patients at high risk of financial distress.
https://t.co/y93gNmz4AL

[Lurie Cancer Center @LurieCancer]

Asking patients for guidance based on their lived experience is key, says Lurie Cancer Center's Laila Gharzai, MD, (@LGharzai), co-author of a recent study about #financialtoxicity screening preferences in @JCOOP_ASCO. "They've actually been through it."

[Laila Gharzai MD LLM @LGharzai]

@ThePinkFund @GelarehSadigh @reshmajagsi

[Laila Gharzai MD LLM @LGharzai]

Excited to share our newest fin tox work—we ask cancer patients for guidance on how best to screen for financial toxicity. Patients tell us that they want screening to be early, often, and initiated by their providers. Important implications for policy.

https://t.co/mnsfhEICWH

[Laila Gharzai MD LLM @LGharzai]

Short summary PRO measures offer the opportunity to frequently screen patients undergoing treatment without unduly burdening patients. We show that FACT GP5, assessing side effect bother, is a promising summary measure for head/neck cancer patients.

https://t.co/w9THHCunaO

[Laila Gharzai MD LLM @LGharzai]

@rajatthawani @OncLive @UChicagoHemOnc @NorthwesternMed @your_hemoncdoc @JPatelMD @DivyaGuptaMD @DrRoyHerbstYale @DrEdKim @JSabari ♥️🥊💜

[Rajat Thawani @rajatthawani]

@OncLive Face-Off between @UChicagoHemOnc and @NorthwesternMed !
Debated lung cancer, while discussing our rivalry!
Purple vs Maroon!
@your_hemoncdoc @JPatelMD @LGharzai @DivyaGuptaMD
With judges @DrRoyHerbstYale @DrEdKim @JSabari

[Laila Gharzai MD LLM @LGharzai]

Poster #282 right now in the exhibit hall!

[Lurie Cancer Center @LurieCancer]

Underway at #ASCO24, Laila Gharzai, MD, @LGharzai, is discussing the impact of biomarker testing in metastatic non-small cell lung cancer during the Quality Care / Health Service Research Session. @NorthwesternMed

[Nadia Samaha @nadiasamaha_]

Check out our paper on screening for financial toxicity in patients with cancer! #LeilaMady @LGharzai @hopkins_ent Preventing and addressing FT begins with detecting it. We discuss the available tools, best practices, and common risk factors. https://t.co/Kj8dVic4n0

[Laila Gharzai MD LLM @LGharzai]

@theabzlab @lesagniksarkar @NorthwesternU @LurieCancer @troyteo @AmulyaYala @JamesRandallMD1 Excellent—looking forward to seeing more and learning how to apply this work prospectively!

[Laila Gharzai MD LLM @LGharzai]

@DrMLChua @JJCaudell Absolutely—our next steps include updating this with newer data!

[James Caudell @JJCaudell]

Surrogate endpoints for HPV+ HN cancer; an analysis of 5 NRG Oncology studies. LRPFS, DMFS, and PFS seem to fit the bill.

https://t.co/QVLPiSVJO5

@LGharzai

[Laila Gharzai MD LLM @LGharzai]

Excited to share our work showing the first validation of surrogate endpoints in HPV+ oropharyngeal cancer! We show that LRPFS, DMFS, and PFS correlate with 5yr OS. Important for trial design in this evolving dx space @MierzwaMichelle @StatMatt9 @NRGonc

https://t.co/iXrUHCaJb4

[JAMA Otolaryngology – Head & Neck Surgery @JAMAOto]

The FACT-HN-RAD offers a means to serially monitor patients with radiation therapy-related adverse effects and recovery over time in both the clinical and research settings. https://t.co/jEDOyZZytR @lgharzai @mierzwamichelle